Anthony Serritella· @aserritella1984 · X·· 10 小时前评分70
正文 · 原文
I always get excited by plenaries at major conferences. Today’s DeLLphi-305 results are an example of seeing the standard of care changing to better patients’ lives. Tarlatamab is finding its most exiting “moment” in MRD-low disease maintenance #ESMO26 #Tarlatamab
105 浏览 · 4 赞 · 1 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Anthony Serritella · x.com